SpringerLink
Log in

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome

  • Educational Series/Red Series
  • Current Technology in Cancer Research and Treatment
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The prognosis of metastatic colorectal cancer remains poor despite advances made in recent years, particularly with new treatments directed towards molecular targets. Cetuximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody that targets the ligand-binding domain of the epidermal growth factor receptor (EGFR), is active in metastatic colorectal cancer. As an IgG1 antibody, cetuximab may exert its antitumour efficacy through both EGFR antagonism and antibody-dependent cell-mediated cytotoxicity. The benefits of cetuximab in metastatic colorectal cancer are well documented in clinical trials and are acknowledged in the approval and licensing of this agent. There is evidence of the role of cetuximab not only in irinotecan-refractory or heavily pretreated patients, but also of the efficacy and safety of the addition of this agent to FOLFIRI (irinotecan/5-fluorouracil/leucovorin) in first-line metastatic colorectal cancer, with an enhanced effect in 5-fluorouracil patients with Kirsten rat sarcoma (KRAS) wild-type tumours. In these patients, a recent meta-analysis of the pooled Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) and Oxaliplatin and Cetuximab in First-Line Treatment of mCRC (OPUS) patient populations confirms that the addition of cetuximab to first-line chemotherapy achieves a statistically significant improvement in the best overall response, overall survival time, and progression-free survival (PSF) compared with chemotherapy alone. In nonresectable colorectal liver metastases, cetuximab plus FOLFOX-6 (oxaliplatin/5-fluorouracil/leucovorin) or cetuximab plus FOLFIRI increased significantly resectability of liver metastases, including R0 resections. Also, preliminary data indicate that cetuximab can be administered in a more convenient 2-week schedule in combination with standard chemotherapy. Cetuximab is generally well tolerated. Acne-form rash is the most frequent toxicity. Up to the present time, the results obtained with targeted therapy combinations are not as encouraging as initially expected. The identification of biomarkers associated with disease control, including KRAS and BRAF mutation status in patients treated with cetuximab, is changing the current management of metastatic colorectal cancer. Clinical and molecular predictive markers of response are under active evaluation in order to better select patients who could benefit from cetuximab treatment, with the aim of both optimising patient outcomes and avoiding unnecessary toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology™. Colon cancer. V.2.2009. Available at http://www.nccn.org

  3. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488

    Article  CAS  PubMed  Google Scholar 

  4. Center MM, Jemal A, Ward E (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18:1688–1694

    Article  PubMed  Google Scholar 

  5. Ribes J, Navarro M, Cèries R et al (2009) Colorectal cancer mortality in Spain: trends and projections for 1985–2019. Eur J Gastroenterol Hepatol 21:92–100

    Article  PubMed  Google Scholar 

  6. Field K, Lipton L (2007) Metastatic colorectal cancer — past, progress and future World J Gastroenterol 13:3806–3815

    CAS  PubMed  Google Scholar 

  7. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

    Article  PubMed  Google Scholar 

  8. Borner MM (1999) Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer — too good to be true? Ann Oncol 10:623–626

    Article  CAS  PubMed  Google Scholar 

  9. Kremeny B (2006) Management of liver metastases from colorectal cancer. Oncology 20:1161–1176

    Google Scholar 

  10. Muratore A, Zorzi D, Bouzari H et al (2007) Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14:766–770

    Article  PubMed  Google Scholar 

  11. Hammoud MA, McCutcheon IE, Elsouki R et al (1996) Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. Ann Surg Oncol 3:453–463

    Article  CAS  PubMed  Google Scholar 

  12. Pestieau SR, Sugarbaker PH (2000) Treatment of primary colon cancer with peritoneal carcinomatosis. Comparison of concomitant vs. delayed management. Dis Colon Rectum 43:1341–1346

    Article  CAS  PubMed  Google Scholar 

  13. Chau I, Allen MJ, Cunningham D et al (2004) The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 22:1420–1429

    Article  CAS  PubMed  Google Scholar 

  14. Desch CE, Benson AB 3rd, Somerfield MR et al (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guidelines. J Clin Oncol 23:8512–8519

    Article  PubMed  Google Scholar 

  15. Wiering B, Vogel WV, Ruers TJ, Oyen WJ (2008) Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg 25:413–420

    Article  PubMed  Google Scholar 

  16. Ogunbiyi OA, Flanagan FL, Dehdashti F et al (1997) Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 4:613–620

    Article  CAS  PubMed  Google Scholar 

  17. de Geus-Oei LF, Ruers TJ, Punt CJ et al (2006) FDG-PET in colorectal cancer. Cancer Imaging 6: S71–S81

    Article  PubMed  Google Scholar 

  18. de Geus-Oei LF, Vriens D, van Laarhoven HW et al (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50(Suppl 1):43S–54S

    Article  PubMed  CAS  Google Scholar 

  19. Tobaruela E, Enriquez JM, Diez M et al (1997) Evaluation of serum carcinoembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level. Int J Biol Markers 12:18–21

    CAS  PubMed  Google Scholar 

  20. Graboń W, Mielczarek-Puta M, Chrzanowskaa A, Barańczyk-Kuźma A (2009) l-Arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer. Clin Biochem 42:353–357

    Article  PubMed  CAS  Google Scholar 

  21. Levine PH, Joutovsky A, Cangiarella J et al (2006) CDX-2 expression in pulmonary fineneedle aspiration specimens: a useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma. Diagn Cytopathol 34:191–195

    Article  PubMed  Google Scholar 

  22. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23:4553–4560

    Article  CAS  PubMed  Google Scholar 

  23. González HD, Figueras J (2007) Practical questions in liver metastases of colorectal cancer: general principles of treatment. HPB (Oxford) 9: 251–258

    Google Scholar 

  24. Erturk SM, Ichikawa T, Fujii H et al (2006) PET imaging for evaluation of metastatic colorectal cancer of the liver. Eur J Radiol 58:229–235

    Article  PubMed  Google Scholar 

  25. Nuzzo G, Giuliante F, Ardito F et al (2008) Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery 143:384–393

    Article  PubMed  Google Scholar 

  26. Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999

    Article  CAS  PubMed  Google Scholar 

  27. Viganò L, Ferrero A, Lo Tesoriere R, Capussotti L (2008) Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol 15:2458–2464

    Article  PubMed  Google Scholar 

  28. Laurent C, Sa Cunha A, Rullier E et al (2004) Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 198:884–891

    Article  PubMed  Google Scholar 

  29. Masi G, Loupakis F, Pollina L et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249:420–425

    Article  PubMed  Google Scholar 

  30. Masi G, Cupini S, Marcucci L et al (2006) Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 13: 58–65

    Article  PubMed  Google Scholar 

  31. Teng LS, Zheng Y, Zhang J (2008) Neoadjuvant chemotherapy for metastatic colorectal cancer to the liver: from chemotherapy to targeting therapy. Hepatobiliary Pancreat Dis Int 6:569–570

    Google Scholar 

  32. Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983–4990

    Article  CAS  PubMed  Google Scholar 

  33. Goldberg RM, Rothenberg ML, Van Cutsem E et al (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12:38–50

    Article  PubMed  Google Scholar 

  34. Van Cutsem E, Hoff PM, Harper P et al (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90:1190–1197

    Article  PubMed  CAS  Google Scholar 

  35. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  36. Hochster HS, Hart LL, Ramanathan RK et al (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 24(Suppl):3510

    Google Scholar 

  37. Fuchs C, Marshall J, Mitchell E et al (2006) A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol 24(Suppl):3506

    Google Scholar 

  38. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905–914

    Article  CAS  PubMed  Google Scholar 

  39. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047

    Article  CAS  PubMed  Google Scholar 

  40. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237

    Article  CAS  PubMed  Google Scholar 

  41. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  CAS  PubMed  Google Scholar 

  42. Colucci G, Gebbia V, Paoletti G et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 23:4866–4875

    Article  CAS  PubMed  Google Scholar 

  43. Souglakos J, Androulakis N, Syrigos K et al (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798–805

    Article  CAS  PubMed  Google Scholar 

  44. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:335–2342

    Article  Google Scholar 

  45. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  46. Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720–1726

    Article  CAS  PubMed  Google Scholar 

  47. Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012

    Article  CAS  PubMed  Google Scholar 

  48. Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217–4223

    Article  CAS  PubMed  Google Scholar 

  49. Díaz-Rubio E, Tabernero J, Gómez-España A et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25:4224–4230

    Article  PubMed  CAS  Google Scholar 

  50. Delaunoit T, Goldberg RM, Sargent DJ et al (2004) Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 101:2170–2176

    Article  CAS  PubMed  Google Scholar 

  51. Goldberg R (2006) Therapy for metastatic colorectal cancer. Oncologist 11:981–987

    Article  CAS  PubMed  Google Scholar 

  52. Arnold D, Siewczynski R, Schmoll HJ (2006) The integration of targeted agents into systemic therapy of metastatic colorectal cancer. Ann Oncol 17(Suppl 10):122–128

    Article  Google Scholar 

  53. Köhne CH, Lenz HJ (2009) Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 14:478–488

    Article  PubMed  CAS  Google Scholar 

  54. Rodriguez J, Zarate R, Bandres E et al (2007) Combining chemotherapy and targeted therapies in metastatic colorectal cancer. Word J Gastroenterol 13:5867–5876

    CAS  Google Scholar 

  55. Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36:748–753

    Article  CAS  PubMed  Google Scholar 

  56. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2:60–65

    Article  Google Scholar 

  57. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2006) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508

    Article  CAS  Google Scholar 

  58. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  59. Saltz L, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 26:2013–2019

    Article  CAS  PubMed  Google Scholar 

  60. Sobrero A, Ackland S, Clarke S et al (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77:113–119

    Article  CAS  PubMed  Google Scholar 

  61. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. doi:10.1093/annonc/mdp233

  62. Cao Y, Tan A, Gao F et al (2009) A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 24:677–695

    Article  PubMed  Google Scholar 

  63. Porebska I, Harlozińska A, Bojarowski T (2000) Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biol 21:105–115

    Article  CAS  Google Scholar 

  64. Saltz I, Rubin M, Hochster H et al (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20. Abstract 7

  65. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  66. Vincenzi B, Santini D, Rabitti C et al (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792–797

    Article  CAS  PubMed  Google Scholar 

  67. Gebbia V, Del Prete S, Borsellino N et al (2006) Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 5: 422–428

    Article  PubMed  Google Scholar 

  68. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319

    Article  CAS  PubMed  Google Scholar 

  69. Wilke H, Glynne-Jones R, Thaler J et al (2008) Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 26:5335–5343

    Article  CAS  PubMed  Google Scholar 

  70. Folprecht G, Lutz MP, Schöffski P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456

    Article  CAS  PubMed  Google Scholar 

  71. Raoul JL, Van Laethem JL, Peeters M et al (2009) Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 9:112

    Article  PubMed  CAS  Google Scholar 

  72. Arnold D, Höhler T, Dittrich C et al (2008) Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 19: 1442–1449

    Article  CAS  PubMed  Google Scholar 

  73. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  74. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

    Article  CAS  PubMed  Google Scholar 

  75. Maiello E, Giuliani F, Gebbia V et al (2007) Cetuximab: clinical results in colorectal cancer. Ann Oncol 18Suppl 6:vi8–vi10

    Article  PubMed  Google Scholar 

  76. Wong SF (2005) Cetixumab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27:684–694

    Article  CAS  PubMed  Google Scholar 

  77. Barnett D, Stevens A, Longson C (2006) Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK. Lancet Oncol 7:807–808

    Article  PubMed  Google Scholar 

  78. Peeters M, Price T, Van Laethem JL (2009) Antiepidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 14:29–39

    Article  CAS  PubMed  Google Scholar 

  79. Wainberg Z, Hecht JR (2006) Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther 6:1229–1235

    Article  CAS  PubMed  Google Scholar 

  80. Wu M, Rivkin A, Pham T (2008) Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 30:14–30

    Article  PubMed  CAS  Google Scholar 

  81. Li S, Schmitz KR, Jeffrey PD et al (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301–311

    Article  CAS  PubMed  Google Scholar 

  82. Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. N Engl J Med 343:905–914

    Article  Google Scholar 

  83. Lenz HJ, Van Cutsem E, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914–4921

    Article  CAS  PubMed  Google Scholar 

  84. Souglakos J, Kalykaki A, Vamvakas L et al (2007) Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 18:305–310

    Article  CAS  PubMed  Google Scholar 

  85. Lenz HF (2007) Cetuximab in the management of colorectal cancer. Biologics 1:77–91

    CAS  PubMed  Google Scholar 

  86. Jonker DJ, Karapetis CS, Moore M et al (2007) Randomized phase III trial of cetuximab monotherapy plus best supportive care [BSC] versus BSC Alone in patients with pretreated metastatic epidermal growth factor receptor [EGFR]-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Proc Am Assoc Cancer Res. Abstract LB-1

  87. Sobrero AF, Fehrenbacher L, Rivera F et al (2007) Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial. Proc Am Assoc Cancer Res. Abstract LB-2

  88. Folprecht G, Gruenberger T, Hartmann JT et al (2009) Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). 2009 ASCO Annual Meeting, Gastrointestinal Cancers Symposium. Abstract 296

  89. Bechstein WO, Lang H, Köhne C et al (2009) Resectability and agreement between surgeons: Review of CT and MR scan of the CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases. J Clin Oncol 27:15 (Suppl). Abstract 4091.

    Google Scholar 

  90. Macarulla T, Ramos J Élez E, Capdevila J et al (2008) Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 7:300–308

    Article  CAS  PubMed  Google Scholar 

  91. Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561

    Article  CAS  PubMed  Google Scholar 

  92. Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572

    Article  CAS  PubMed  Google Scholar 

  93. Simi L, Prateso N, Vignoli M et al (2008) High resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130:247–253

    Article  CAS  PubMed  Google Scholar 

  94. Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237

    Article  CAS  PubMed  Google Scholar 

  95. van Krieken JH, Jung A, Kirchner T et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchow Arch 453:417–431

    Article  CAS  Google Scholar 

  96. Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972

    Article  CAS  PubMed  Google Scholar 

  97. Amado RG, Wolf M, Peeters M et al (2008) Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  CAS  PubMed  Google Scholar 

  98. Lièvre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Cin Oncol 26:374–379

    Article  CAS  Google Scholar 

  99. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648

    Article  CAS  PubMed  Google Scholar 

  100. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515

    Article  PubMed  Google Scholar 

  101. Finocchiaro G, Cappuzzo F, Jänne PA et al (2007) EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 25(Suppl): 4021

    Google Scholar 

  102. Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 23: 1166–1169

    Article  CAS  Google Scholar 

  103. Lièvre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

    Article  PubMed  Google Scholar 

  104. Cervantes A, Macarulla T, Martinelli E et al (2008) Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 26(Suppl). Abstract 4129

  105. Van Cutsem E, Lang I, D’haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26(Suppl). Abstract 2

  106. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  CAS  PubMed  Google Scholar 

  107. Bokemeyer C, Bondarenko I, Hartmann JT et al (2008) KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26(Suppl). Abstract 4000

    Google Scholar 

  108. Punt CJ, Tol J, Rodenburg CJ et al (2008) Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(Suppl). Abstract LBA4011

  109. Winer E, Gralow J, Diller L et al (2009) Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 27:812–816

    Article  PubMed  Google Scholar 

  110. Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096

    Article  PubMed  Google Scholar 

  111. National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in colon/rectal cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed March 8, 2010

  112. Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M et al (2010) Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci 101:1080–1088

    Article  CAS  PubMed  Google Scholar 

  113. Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129

    Article  CAS  PubMed  Google Scholar 

  114. Van Cutsem E, Lang I, Folprecht G et al (2010) Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. ASCO 2010. Gastrointestinal Cancers Symposium. Abstract 281

  115. Bokemeyer C, Bondarenko I, Hartmann JT et al (2010) Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOFOX4 plus or minus cetuximab: updated data from the OPUS study. ASCO 2010. Gastrointestinal Cancers Symposium. Abstract 428

  116. Kohne C, Rougier P, Stroh C et al (2010) Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO 2010. Gastrointestinal Cancers Symposium. Abstract 406

  117. Tsiatis AC, Norris-Kirby A, Rich RG et al (2009) Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations. Diagnostic and clinical implications. J Mol Diagn doi:10.2353/jmoldx.2010.090188

  118. Weichert W, Schewe C, Lehmann A et al (2010) KRAS genoty** of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 12:35–42

    Article  CAS  PubMed  Google Scholar 

  119. Zuo Z, Chen SS, Chandra PK et al (2009) Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 22:1023–1031

    Article  CAS  PubMed  Google Scholar 

  120. Franklin WA, Haney J, Sugita M (2010) KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 12:43–50

    Article  CAS  PubMed  Google Scholar 

  121. Su X, Lacouture ME, Jia Y, Wu S (2009) Risk of high-grade skin rash in cancer patients treated with cetuximab—an antibody against epidermal growth factor receptor: systemic review and metaanalysis. Oncology 77:124–133

    Article  CAS  PubMed  Google Scholar 

  122. Bernier J, Bonner J, Vermorken JB et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy and EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142–149

    Article  CAS  PubMed  Google Scholar 

  123. Folprecht G, Nowacki M, Lang I et al (2009) Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): a quality-of-life (QoL) analysis of the CRYSTAL trial. J Clin Oncol 27:15s (Suppl). Abstract 4076

    Google Scholar 

  124. Siena S, Glynne-Jones R, Thaler J et al (2007) MABEL — A large multinational study of cetuximab plus irinotecan in irinotecan-resistant metastatic colorectal cancer: Update on infusion related reactions (IRR). ASCO 2007. Gastrointestinal Cancers Symposium. Abstract 353

  125. Fakih MG, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6:152–156

    Article  CAS  PubMed  Google Scholar 

  126. Vincenzi B, Santini D, Galluzzo S et al (2008) Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of early efficacy and outcome. Clin Cancer Res 14:4219. doi:10.1158/1078-0432

    Article  CAS  PubMed  Google Scholar 

  127. Au HJ, Karapetis CS, O’Callaghan CJ et al (2009) Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 27: 1822–1828

    Article  CAS  PubMed  Google Scholar 

  128. Ramanathan RK (2008) Alternative dosing schedules for cetuximab: a role for biweekly administration? Clin Colorectal Cancer 7:364–368

    Article  CAS  PubMed  Google Scholar 

  129. Mrabti H, De la Fouchardiere C, Desseigne F et al (2009) Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J Cancer Res Ther 5: 272–276

    Article  CAS  PubMed  Google Scholar 

  130. Tabernero J, Pfeiffer P, Cervantes A (2008) Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 13:113–119

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Clínica Universitaria de Navarra, Pamplona, Navarra, Spain

    Jesús García-Foncillas

  2. Servicio de Oncología Médica, Hospital Clínico San Carlos, C/ Dr. Martín Lagos, s/n, ES-28040, Madrid, Spain

    Eduardo Díaz-Rubio

Authors
  1. Jesús García-Foncillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduardo Díaz-Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Díaz-Rubio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

García-Foncillas, J., Díaz-Rubio, E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 12, 533–542 (2010). https://doi.org/10.1007/s12094-010-0551-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-010-0551-3

Keywords (MeSH terms)

Search

Navigation